41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Promoting public awareness of the need for education, research, treatment and a cure for diseases, conditions and disorders relating to seizures Providing an online forum for transmission of messages concerning diseases, conditions and disorders relating to seizures Entertainment and educational services, namely, providing live and online seminars, conferences and workshops concerning diseases, conditions and disorders relating to seizures, and distributing informational course materials in connection therewith Hosting an on-line community website featuring information related to seizures; computer services, namely, creating an on-line community for registered users to participate in discussions, get feedback from their peers, form virtual communities, and engage in social networking concerning seizures; Providing a website featuring technology that enables users to search, watch, share, and comment on documents, videos, audio and other multimedia content concerning issues related to seizures Providing health information; providing information and online information relating to diagnostic, prophylactic and therapeutic properties of pharmaceutical preparations for the prevention and treatment of diseases, disorders and conditions relating to seizures
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Promoting public awareness of the need for education, research, treatment and a cure for diseases, conditions and disorders relating to seizures Providing an online forum for transmission of messages concerning diseases, conditions and disorders relating to seizures Entertainment and educational services, namely, providing live and online seminars, conferences and workshops concerning diseases, conditions and disorders relating to seizures, and distributing informational course materials in connection therewith Hosting an on-line community website featuring information related to seizures; computer services, namely, creating an on-line community for registered users to participate in discussions, get feedback from their peers, form virtual communities, and engage in social networking concerning seizures; Providing a website featuring technology that enables users to search, watch, share, and comment on documents, videos, audio and other multimedia content concerning issues related to seizures Providing health information; providing information and online information relating to diagnostic, prophylactic and therapeutic properties of pharmaceutical preparations for the prevention and treatment of diseases, disorders and conditions relating to seizures
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products, namely, pharmaceutical and biological preparations used in the treatment of diseases, disorders or conditions of the nervous system
Medical devices, namely, drug delivery system in the nature of an oral inhaler that facilitates the delivery of pharmaceutical and biological preparations used in the treatment of diseases, disorders or conditions of the nervous system
Medical devices, namely, drug delivery system in the nature of an oral inhaler that facilitates the delivery of pharmaceutical and biological preparations used in the treatment of diseases, disorders or conditions of the nervous system
Medical devices, namely, drug delivery system in the nature of an oral inhaler that facilitates the delivery of pharmaceutical and biological preparations used in the treatment of diseases, disorders or conditions of the nervous system
Medical devices, namely, drug delivery system in the nature of an oral inhaler that facilitates the delivery of pharmaceutical and biological preparations used in the treatment of diseases, disorders or conditions of the nervous system
Medical devices, namely, drug delivery system in the nature of an oral inhaler that facilitates the delivery of pharmaceutical and biological preparations used in the treatment of diseases, disorders or conditions of the nervous system
Disclosed herein are methods and compositions for treating a subject with central nervous system injury. In some embodiments, a method of treating a subject with CNS injury comprises administering to the subject in need thereof a composition comprising an effective amount of a proteoglycan degrading domain. In some embodiments, administering near the site of injury comprises injecting a first amount of the composition at a first depth, and injecting a second amount of the composition at a second depth, wherein the second depth is greater than the first depth, and wherein the first depth and the second depth are at the same site of administration.
The present invention provides carbonate prodrugs which comprise a carbonic phosphoric anhydride prodrug moiety attached to the hydroxyl or carboxyl group of a parent drug moiety. The prodrugs may provide improved physicochemical properties over the parent drug. Also provided are methods of treating a disease or condition that is responsive to the parent drug using the carbonate prodrugs, as well as kits and unit dosages.
A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
C07C 233/25 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
C07F 9/11 - Esters of phosphoric acids with hydroxyalkyl compounds without further substituents on alkyl
11.
Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
The invention relates to treatment of heart failure in a mammal. Accordingly, the invention is directed to establishing a dosing regimen whereby the therapeutic benefits conferred by administration of a neuregulin such as glial growth factor 2 (GGF2) or a subsequence thereof are maintained and/or enhanced, while concomitantly minimizing any potential side effects.
The present invention provides water-soluble acetaminophen prodrugs and formulations which may be suitable for parenteral administration. Methods of treating a disease or condition responsive to acetaminophen (such as fever and/or pain) using the acetaminophen prodrugs, as well as kits, unit dosages, and combinations with additional pharmaceutical agent(s) are also provided.
A61P 29/02 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 25/04 - Centrally acting analgesics, e.g. opioids
A61P 25/00 - Drugs for disorders of the nervous system
A61P 43/00 - Drugs for specific purposes, not provided for in groups
The present invention relates to a method for detecting heart damage in a patient. The invention also relates to methods for treatment of patients identified as having heart damage. The invention further pertains to methods for evaluating the efficacy of an ongoing therapeutic regimen designated to treat a damaged heart in a patient.
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Providing campaigns featuring information to promote public awareness regarding Parkinson's disease. Providing health information regarding Parkinson's disease.
15.
Method for achieving desired glial growth factor 2 plasma levels
The present invention relates to administering glial growth factor 2 (GGF2) to a patient in need thereof, to achieve serum levels of GGF2 within a desired therapeutic window determined based on the disease or disorder afflicting the patient. In a particular embodiment, the patient is suffering from a disease or disorder associated with reduced levels of myelination and the GGF2 is administered to promote myelination in the patient.
The present mention relates to a method for detecting heart damage in a patient. The invention also relates to methods for treatment of patients identified as having heart damage. The invention further pertains to methods for evaluating the efficacy of an ongoing therapeutic regimen designated to treat a damaged heart in a patient.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
(1) Pharmaceutical products, namely, pharmaceutical and biological preparations for the treatment of diseases, disorders and conditions of the nervous system namely brain, movement, ocular motility, autoimmune and spinal cord diseases, disorders and conditions; pharmaceutical and biological preparations for the treatment of Parkinson's Disease, multiple sclerosis, Alzheimer's Disease and epilepsy
(2) Medical devices, namely inhaler and nebulizer delivery devices that facilitate delivery of pharmaceutical and biological preparations used in the treatment of diseases, disorders and conditions of the nervous system
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
(1) Pharmaceutical products, namely, pharmaceutical and biological preparations for the treatment of diseases, disorders and conditions of the nervous system namely brain, movement, ocular motility, autoimmune and spinal cord diseases, disorders and conditions; pharmaceutical and biological preparations for the treatment of Parkinson's Disease, multiple sclerosis, Alzheimer's Disease and epilepsy
(2) Medical devices, namely inhaler and nebulizer delivery devices that facilitate delivery of pharmaceutical and biological preparations used in the treatment of diseases, disorders and conditions of the nervous system
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical and biological preparations used in the treatment of diseases, disorders or conditions of the nervous system. Medical devices, namely, drug delivery system that facilitates the delivery of pharmaceutical and biological preparations used in the treatment of diseases, disorders or conditions of the nervous system.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical and biological preparations used in the treatment of diseases, disorders or conditions of the nervous system. Medical devices, namely, drug delivery system that facilitates the delivery of pharmaceutical and biological preparations used in the treatment of diseases, disorders or conditions of the nervous system.
The present invention generally relates to sustained release 4-aminopyridine tablets, which include a core and a coating. The sustained release tablets of the invention are generally suitable for once daily oral administration for the treatment of neurological disorders.
One aspect of the present invention relates to mutants of chondroitinase ABCI. Such chondroitinase ABCI mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.
C12P 21/06 - Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C07K 1/00 - General processes for the preparation of peptides
The present invention provides carbonate prodrugs which comprise a carbonic phosphoric anhydride prodrug moiety attached to the hydroxyl or carboxyl group of a parent drug moiety. The prodrugs may provide improved physicochemical properties over the parent drug. Also provided are methods of treating a disease or condition that is responsive to the parent drug using the carbonate prodrugs, as well as kits and unit dosages.
C07F 9/11 - Esters of phosphoric acids with hydroxyalkyl compounds without further substituents on alkyl
C07C 233/25 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
25.
Method for achieving desired glial growth factor 2 plasma levels
The present invention relates to administering glial growth factor 2 (GGF2) to a patient in need thereof, to achieve serum levels of GGF2 within a desired therapeutic window determined based on the disease or disorder afflicting the patient. In a particular embodiment, the patient is suffering from a disease or disorder associated with reduced levels of myelination and the GGF2 is administered to promote myelination in the patient.
The present invention provides hepatoprotectant acetaminophen mutual prodrugs, which have an acetaminophen moiety covalently linked to a second moiety that may act as a hepatoprotectant against acetaminophen hepatotoxicity. Additionally, acetaminophen mutual prodrugs may have improved water solubility which may provide better suitability for parenteral and other dosage forms relative to administration of acetaminophen. Also provided are methods of treating a disease or condition that is responsive to acetaminophen (such as fever, pain and ischemic injury) using hepatoprotectant acetaminophen mutual prodrugs, as well as kits and unit dosages.
C07C 323/52 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
27.
Compositions and methods for promoting neuronal outgrowth
Neural outgrowth in the central nervous system is achieved by administering chondroitinase AC and/or chondroitinase B to degrade chondroitin sulfate proteoglycans that inhibit or contribute to the inhibition of nervous tissue regeneration.
The present invention relates to a method for detecting heart damage in a patient. The invention also relates to methods for treatment of patients identified as having heart damage. The invention further pertains to methods for evaluating the efficacy of an ongoing therapeutic regimen designated to treat a damaged heart in a patient.
The invention relates to treatment of heart failure in a mammal. Accordingly, the invention is directed to establishing a dosing regimen whereby the therapeutic benefits conferred by administration of a neuregulin such as glial growth factor 2 (GGF2) or a subsequence thereof are maintained and/or enhanced, while concomitantly minimizing any potential side effects.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical products, namely, pharmaceutical and biological preparations used in the treatment of diseases, disorders or conditions of the nervous system. Medical devices, namely delivery devices that facilitate delivery of pharmaceutical and biological preparations used in the treatment of diseases, disorders or conditions of the nervous system.
(1) Medical devices, namely inhaler and nebulizer delivery devices that facilitate delivery of pharmaceutical and biological preparations used in the treatment of diseases, disorders and conditions of the nervous system
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical products, namely, pharmaceutical and biological preparations for the treatment of diseases, disorders and conditions of the nervous system namely brain, movement, ocular motility, autoimmune and spinal cord diseases, disorders and conditions; pharmaceutical and biological preparations for the treatment of Parkinson's Disease, multiple sclerosis, Alzheimer's Disease and epilepsy.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical products, namely, pharmaceutical and biological preparations used in the treatment of diseases, disorders or conditions of the nervous system. Medical devices, namely delivery devices that facilitate delivery of pharmaceutical and biological preparations used in the treatment of diseases, disorders or conditions of the nervous system.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical products, namely, pharmaceutical and biological preparations used in the treatment of diseases, disorders or conditions of the nervous system. Medical devices, namely delivery devices that facilitate delivery of pharmaceutical and biological preparations used in the treatment of diseases, disorders or conditions of the nervous system.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical products, namely, pharmaceutical and biological preparations for the treatment of diseases, disorders and conditions of the nervous system namely brain, movement, ocular motility, autoimmune and spinal cord diseases, disorders and conditions; pharmaceutical and biological preparations for the treatment of Parkinson's Disease, multiple sclerosis, Alzheimer's Disease and epilepsy
36.
Compositions and methods of using chondroitinase ABCI mutants
The present disclosure relates to protein and nucleic acid mutants of chondroitinase ABCI. Such nucleic acid mutants encode for chondroitinase ABCI mutant enzymes exhibiting altered chondroitin lyase activity or increased resistance to inactivation from stressors including UV light or heat. Methods of using such nucleic acid mutants encoding chondroitinase ABCI mutant enzymes is also provided.
C12N 15/64 - General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
C12P 21/06 - Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C07K 1/00 - General processes for the preparation of peptides
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventor
Gruskin, Elliott A.
Warrington, Arthur E.
Bieber, Allan J.
Rodriguez, Moses
Chojnicki, Eric Walter Theodore
Abstract
Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like. The invention also extends to the use of human antibodies, fragments, peptide derivatives and like materials, and their use in above referenced therapeutic applications, and to pharmaceutical compositions containing them, that may be administered in desirably low doses to treat conditions involving demyelination and to promote remyelination.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
A61K 39/00 - Medicinal preparations containing antigens or antibodies
38.
Compositions and methods of using chondroitinase ABCI mutants
One aspect of the present invention relates to mutants of chondroitinase ABCI. Such chondroitinase ABCI mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C07K 1/00 - General processes for the preparation of peptides
Neural outgrowth in the central nervous system is achieved by administering chondroitinase AC and/or chondroitinase B to degrade chondroitin sulfate proteoglycans that inhibit or contribute to the inhibition of nervous tissue regeneration.
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Promoting public awareness of the need for education, research, treatment and a cure for diseases, disorders and conditions. Entertainment and educational services, namely, providing live and online seminars, conferences and workshops concerning issues related to diseases, disorders and conditions and distributing informational course materials in connection therewith. Providing health information; providing information and online information relating to diagnostic, prophylactic and therapeutic properties of pharmaceutical preparations for the prevention and treatment of diseases, disorders and conditions.
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Promoting public awareness of the need for education, research, treatment and a cure for diseases, disorders and conditions. Entertainment and educational services, namely, providing live and online seminars, conferences and workshops concerning issues related to diseases, disorders and conditions and distributing informational course materials in connection therewith. Providing health information; providing information and online information relating to diagnostic, prophylactic and therapeutic properties of pharmaceutical preparations for the prevention and treatment of diseases, disorders and conditions.
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Promoting public awareness of the need for education, research, treatment and a cure for diseases, disorders and conditions. Entertainment and educational services, namely, providing live and online seminars, conferences and workshops concerning issues related to diseases, disorders and conditions and distributing informational course materials in connection therewith. Providing health information; providing information and online information relating to diagnostic, prophylactic and therapeutic properties of pharmaceutical preparations for the prevention and treatment of diseases, disorders and conditions.
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Promoting public awareness of the need for education, research, treatment and a cure for diseases, disorders and conditions of the central nervous system; Entertainment and educational services, namely, providing live and online seminars, conferences and workshops concerning issues related to diseases, disorders and conditions of the central nervous system and distributing informational course materials in connection therewith; Providing health information about issues related to diseases, disorders and conditions of the central nervous system; providing information and online information relating to diagnostic, prophylactic and therapeutic properties of pharmaceutical preparations for the prevention and treatment of diseases, disorders and conditions of the central nervous system.
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Promoting public awareness of the need for education, research, treatment and a cure for diseases, disorders and conditions of the central nervous system; Entertainment and educational services, namely, providing live and online seminars, conferences and workshops concerning issues related to diseases, disorders and conditions of the central nervous system and distributing informational course materials in connection therewith; Providing health information about issues related to diseases, disorders and conditions of the central nervous system; providing information and online information relating to diagnostic, prophylactic and therapeutic properties of pharmaceutical preparations for the prevention and treatment of diseases, disorders and conditions of the central nervous system.
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Promoting public awareness of the need for education, research, treatment and a cure for diseases, disorders and conditions of the central nervous system; Entertainment and educational services, namely, providing live and online seminars, conferences and workshops concerning issues related to diseases, disorders and conditions of the central nervous system and distributing informational course materials in connection therewith; Providing health information about issues related to diseases, disorders and conditions of the central nervous system; providing information and online information relating to diagnostic, prophylactic and therapeutic properties of pharmaceutical preparations for the prevention and treatment of diseases, disorders and conditions of the central nervous system.
The present invention relates to a method for detecting heart damage in a patient. The invention also relates to methods for treatment of patients identified as having heart damage. The invention further pertains to methods for evaluating the efficacy of an ongoing therapeutic regimen designated to treat a damaged heart in a patient.
Disclosed herein are methods and compositions related to therapeutic use of aminopyridines in patients with stroke-related impairments, in particular, in patients with sensorimotor impairments resulting from certain types of stroke.
A61K 31/4409 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 25/00 - Drugs for disorders of the nervous system
48.
THERAPEUTIC DOSING OF A NEUREGULIN OR A FRAGMENT THEREOF FOR TREATMENT OR PROPHYLAXIS OF HEART FAILURE
The invention relates to treatment and prevention of heart failure in a mammal. The invention provides a dosing regimen whereby the therapeutic benefits conferred by administration of peptide comprising an epidermal growth factor-like domain, e.g., a neuregulin such as glial growth factor 2 (GGF2) or a functional fragment thereof, are maintained and/or enhanced, while concomitantly minimizing any potential side effects.
Provided herein are methods and compositions for treatment of patients with Parkinson's disease and, in particular, motor impairments in patients with Parkinson's disease, using an aminopyridine.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical and biological preparations used in the treatment of diseases, disorders or conditions of the nervous system, namely, epileptic seizure clusters and acute repetitive seizures.
51.
METHODS FOR IMPROVING WALKING CAPACITY IN PATIENTS WITH MULTIPLE SCLEROSIS USING AN AMINOPYRIDINE
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The present invention relates to administering glial growth factor 2 (GGF2) to a patient in need thereof, to achieve serum levels of GGF2 within a desired therapeutic window determined based on the disease or disorder afflicting the patient. In a particular embodiment, the patient is suffering from a disease or disorder associated with reduced levels of myelination and the GGF2 is administered to promote myelination in the patient.
The invention relates to treatment of heart failure in a mammal. Accordingly, the invention is directed to establishing a dosing regimen whereby the therapeutic benefits conferred by administration of a neuregulin such as glial growth factor 2 (GGF2) or a subsequence thereof are maintained and/or enhanced, while concomitantly minimizing any potential side effects.
Mayo Foundation for Medical Education & Research (USA)
Acorda Therapeutics, Inc. (USA)
Inventor
Gruskin, Elliot A.
Chojnicki, Eric
Warrington, Arthur E.
Bieber, Allan J.
Rodriguez, Moses
Abstract
Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like. The invention also extends to the use of human antibodies, fragments, peptide derivatives and like materials, and their use in above referenced therapeutic applications, and to pharmaceutical compositions containing them, that may be administered in desirably low doses to treat conditions involving demyelination and to promote remyelination.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
A61K 39/00 - Medicinal preparations containing antigens or antibodies
56.
USE OF NEUREGULIN TO TREAT PERIPHERAL NERVE INJURY
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
Disclosed herein is use of one or more aminopyridines in methods and compositions for treatment of impairments in gait or balance in patients with multiple sclerosis.
Disclosed herein are methods and compositions related to therapeutic use of aminopyridines in patients with a stroke-related impairment, in particular, in patients with a stroke-related sensorimotor impairment.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 25/00 - Drugs for disorders of the nervous system
59.
ACETAMINOPHEN CONJUGATES, COMPOSITIONS AND METHODS OF USE THEREOF
Acetaminophen conjugates are provided, which have an acetaminophen moiety covalently linked to a second moiety. The conjugates provided may have one or more advantageous properties, including increased water solubility as compared to acetaminophen, reduced toxicity profile as compared to acetaminophen and an altered pharmacokinetic profile. Formulations comprising the conjugates are also provided, as are methods of using the conjugates and kits comprising the conjugates.
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
SK BIOPHARMACEUTICALS CO., LTD. (Republic of Korea)
Inventor
Bream, Gary
Khayrallah, Moise, A.
Baek, Myoung-Ki
Jo, Jae-Hoon
Chang, Hye-Jin
Abstract
The present invention generally relates to intranasal pharmaceutical compositions comprising a benzodiazepine and methods of use thereof that can provide a therapeutic effect without a decrease in blood pressure and/or pulse after administration of the pharmaceutical composition.
A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
Disclosed herein is the use of aminopyridines, such as 3-aminopyridine, 4-aminopyridine or 3,4-diaminopyridine, in the management and treatment of cerebral palsy patients of all ages.
A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.
Embodiments of the invention are directed to use of neuregulins to prevent or treat peripheral nerve injury, to attenuate, ameliorate or avoid the loss of peripheral nerve function.
The present invention relates to a method for detecting heart damage in a patient. The invention also relates to methods for treatment of patients identified as having heart damage. The invention further pertains to methods for evaluating the efficacy of an ongoing therapeutic regimen designated to treat a damaged heart in a patient.
Disclosed herein are methods and compositions related to the durable use of aminopyridines, such as 4-aminopyridine, to improve impairments of patients with a demyelinating condition, such as MS.
A01N 37/18 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N, e.g. carboxylic acid amides or imidesThio-analogues thereof
05 - Pharmaceutical, veterinary and sanitary products
35 - Advertising and business services
38 - Telecommunications services
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical and biological preparations used in the treatment of neurological diseases, disorders or conditions Promoting public awareness of the need for education, research, treatment and a cure for neurological and mobility diseases and disorders Providing an online forum for transmission of messages concerning issues related to neurological diseases, disorders or conditions Entertainment and educational services, namely, providing live and online seminars, conferences and workshops concerning issues related to neurological diseases, disorders and conditions and distributing informational course materials in connection therewith Hosting an on-line community website featuring information related to neurologic disorders; computer services, namely, creating an on-line community for registered users to participate in discussions, get feedback from their peers, form virtual communities, and engage in social networking concerning issues related to neurologic disorders; Providing a website featuring technology that enables users to search, watch, share, and comment on documents, videos, audio and other multimedia content concerning issues related to neurologic disorders Providing information and online information relating to diagnostic, prophylactic and therapeutic properties of pharmaceutical preparations for the prevention and treatment of diseases, disorders and conditions
05 - Pharmaceutical, veterinary and sanitary products
35 - Advertising and business services
38 - Telecommunications services
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical and biological preparations used in the treatment of neurological diseases, disorders or conditions Promoting public awareness of the need for education, research, treatment and a cure for neurological and mobility diseases and disorders Providing an online forum for transmission of messages concerning issues related to neurological diseases, disorders or conditions Entertainment and educational services, namely, providing live and online seminars, conferences and workshops concerning issues related to neurological diseases, disorders and conditions and distributing informational course materials in connection therewith Hosting an on-line community website featuring information related to neurologic disorders; computer services, namely, creating an on-line community for registered users to participate in discussions, get feedback from their peers, form virtual communities, and engage in social networking concerning issues related to neurologic disorders; Providing a website featuring technology that enables users to search, watch, share, and comment on documents, videos, audio and other multimedia content concerning issues related to neurologic disorders Providing information and online information relating to diagnostic, prophylactic and therapeutic properties of pharmaceutical preparations for the prevention and treatment of diseases, disorders and conditions
72.
USE OF 4-AMINOPYRIDINE TO IMPROVE NEURO-COGNITIVE AND/OR NEURO-PSYCHIATRIC IMPAIRMENT IN PATIENTS WITH DEMYELINATING AND OTHER NERVOUS SYSTEM CONDITIONS
Disclosed herein are methods and compositions related to use of aminopyridines, such as 4-aminopyridine, to improve the neuro -cognitive impairments and related neuro- psychiatric impairments of patients with a demyelinating condition such as MS, traumatic brain injury, cerebral palsy, post-radiation encephalopathy.
A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
The present invention relates to protein and nucleic acid mutants of chondroitinase ABCI. Such chondroitinase ABCI mutant enzymes exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C07K 1/00 - General processes for the preparation of peptides
A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
74.
Compositions and methods of using chondroitinase ABCI mutants
One aspect of the present invention relates to mutants of chondroitinase ABCI. Such chondroitinase ABCI mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.
C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
C12Q 1/34 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C07K 1/00 - General processes for the preparation of peptides
Disclosed herein are methods and compositions related to use of aminopyridines, such as 4-aminopyridine, for use in a therapeutically effective manner for patients with a demyelinating condition, such as multiple sclerosis.
Disclosed herein are methods and compositions related to use of aminopyridines, such as 4-aminopyridine, for use in a therapeutically effective manner for patients with a demyelinating condition, such as multiple sclerosis.
A process for determining responders in clinical testing environments that involves, inter alia, detecting treatment response through the use of small numbers of measurements of randomly varying outcome variables in individual clinical trial subjects, and by analyzing the measurements in such a way as to eliminate troublesome variables, such as a spontaneous population variability.
G06Q 50/00 - Information and communication technology [ICT] specially adapted for implementation of business processes of specific business sectors, e.g. utilities or tourism
78.
THERAPEUTIC DOSING OF A NEUREGULIN OR A SUBSEQUENCE THEREOF FOR TREATMENT OR PROPHYLAXIS OF HEART FAILURE
The invention relates to treatment of heart failure in a mammal. Accordingly, the invention is directed to establishing a dosing regimen whereby the therapeutic benefits conferred by administration of a neuregulin such as glial growth factor 2 (GGF2) or a subsequence thereof are maintained and/or enhanced, while concomitantly minimizing any potential side effects.
Disclosed herein are methods and compositions related to use of aminopyridines, such as fampridine, to improve impairments of patients with a demyelinating condition, such as MS.
A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
81.
Method for achieving desired glial growth factor 2 plasma levels
The present invention relates to administering glial growth factor 2 (GGF2) to a patient in need thereof, to achieve serum levels of GGF2 within a desired therapeutic window determined based on the disease or disorder afflicting the patient. In a particular embodiment, the patient is suffering from a disease or disorder associated with reduced levels of myelination and the GGF2 is administered to promote myelination in the patient.
The present invention relates to administering glial growth factor 2 (GGF2) to a patient in need thereof, to achieve serum levels of GGF2 within a desired therapeutic window determined based on the disease or disorder afflicting the patient. In a particular embodiment, the patient is suffering from a disease or disorder associated with reduced levels of myelination and the GGF2 is administered to promote myelination in the patient.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and biological preparations, products and formulations used in the treatment of spinal cord injuries, multiple sclerosis and other neurological or musculoskeletal diseases, disorders or conditions.
84.
Methods of purifying chondroitinase and stable formulations thereof
An aspect of the present invention relates to stable formulations of chondroitinase and to methods of purifying chondroitinase. The methods of purifying chondroitinase includes the steps of extracting the enzyme from a cell, separating the chondroitinase from the crude cell extract using cation-exchange chromatography, removing impurities through gel filtration chromatography, and removing endotoxin through an anion-exchange membrane to produce a purified chondroitinase.
A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
The present invention relates to a method for detecting heart damage in a patient. The invention also relates to methods for treatment of patients identified as having heart damage. The invention further pertains to methods for evaluating the efficacy of an ongoing therapeutic regimen designed to treat a damaged heart in a patient.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
86.
COMPOSITIONS AND METHODS OF USING CHONDROITINASE ABCI MUTANTS
The present invention relates to protein and nucleic acid mutants of chondroitinase ABCI. Such chondroitinase ABCI mutant enzymes exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.
C12P 21/06 - Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
One aspect of the present invention relates to mutants of chondroitinase ABCI. Such chondroitinase ABCI mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.
C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
88.
Compositions and methods including a recombinant human MAB that promotes CNS remyelination
Mayo Foundation for Medical Education and Research (USA)
Acorda Therapeutics, Inc. (USA)
Inventor
Gruskin, Elliot A.
Chojnicki, Eric
Warrington, Arthur E.
Bieber, Allan J.
Rodriguez, Moses
Abstract
Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like. The invention also extends to the use of human antibodies, fragments, peptide derivatives and like materials, and their use in above referenced therapeutic applications, and to pharmaceutical compositions containing them, that may be administered in desirably low doses to treat conditions involving demyelination and to promote remyelination.
A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.
